文献速递皮肤肿瘤

西班牙皮肤恶性黑色素瘤死亡率1979至2018年趋势及免疫治疗时代新视角

Cutaneous malignant melanoma mortality in Spain from 1979 to 2018. Trends and new perspectives in the immunotherapy era.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-11-29

该研究基于西班牙国家统计局死亡记录与年中人口数据,分析1979至2018年皮肤黑色素瘤死亡率趋势。年龄标化死亡率从1979-1983年的0.78例/10万升至2014-2018年的2.13例/10万,1995年前显著上升后趋于平稳,2015至2018年总体死亡率下降(AAPC:-4.3,无统计学显著性),男性64岁以上更明显。结论认为诊断改进与晚期黑色素瘤新疗法可能起关键作用,需密切监测确认趋势。

要点

  • 西班牙皮肤黑色素瘤年龄标化死亡率从1979-1983年0.78例/10万升至2014-2018年2.13例/10万。
  • 死亡率1995年前显著上升后趋稳,2015至2018年总体下降(AAPC:-4.3,无统计学显著性)。
  • 男性64岁以上死亡率下降更明显,21世纪初起观察到时期效应且死亡率持续下降。

核心结论

  • 2015年起西班牙各年龄组黑色素瘤死亡率下降,证实了年轻队列先前趋势。
  • 诊断改进与晚期黑色素瘤新疗法可能对该事件起关键作用。

研究设计与样本

  • 基于西班牙国家统计局死亡记录与年中人口数据的死亡率趋势分析。
  • 采用直接法计算总体及按性别、年龄组的年龄标化死亡率。
  • 使用Joinpoint回归识别死亡率趋势显著变化,并分析年龄、时期、队列独立效应及潜在减寿年数。

主要发现

  • 总体年龄标化死亡率从1979-1983年0.78例/10万升至2014-2018年2.13例/10万。
  • 死亡率1995年前显著上升后趋于平稳。
  • 2015至2018年总体死亡率下降,平均年度变化百分比(AAPC)为-4.3,无统计学显著性。
  • 男性64岁以上死亡率下降更明显。
  • 21世纪初起观察到时期效应,死亡率至今持续下降。

临床怎么用

  • 皮肤科医生应关注黑色素瘤死亡率在免疫治疗时代可能出现的下降趋势。
  • 临床实践中需重视早期诊断与晚期黑色素瘤新疗法的应用。
  • 需密切监测黑色素瘤死亡率以确认趋势变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent studies suggest that cutaneous melanoma mortality rates in Spain are stabilizing and even decreasing in younger cohorts. OBJECTIVES: To analyse mortality rates of melanoma from the last 40 years, focusing on changes related with the development of new therapeutic approaches. METHODS: Death records and mid-year population data were collected from the National Statistics Institute. By using the direct method, age-standardized mortality rates were calculated for overall population and for each sex and age group. Significant changes in mortality trends were identified by Joinpoint regressions. The independent effects of age, period and cohort (APC) and potential years of life lost (PYLL) due to melanoma were also analysed. RESULTS: Age-standardized melanoma mortality rates rose in Spain from 0.78 to 2.13 deaths per 100 000 from the first to the last quinquennium of the study (1979-1983 to 2014-2018) for the overall population. After a marked increase until 1995, mortality rates levelled off. Following this stabilization, from 2015 to 2018 there was a decrease in mortality rates for the overall population (average annual per cent change (AAPC): -4.3, not significant), more accused in males over 64 years old (yo). A period effect was observed from the beginning of 21st century, with mortality rates dropping to date. CONCLUSIONS: There is a decrease in melanoma mortality rates from 2015 in all age groups that confirms previous trends in mortality in younger cohorts. Improvement in diagnosis and development of new therapies for advanced melanoma may have a crucial role in this event. Close monitoring of melanoma mortality rates is necessary to confirm these trends.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Durán-Romero AJ, Sendín-Martin M, Conejo-Mir J, et al. Cutaneous malignant melanoma mortality in Spain from 1979 to 2018. Trends and new perspectives in the immunotherapy era. J Eur Acad Dermatol Venereol. 2020. PMID: 33030772. doi:10.1111/jdv.16983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。